RBC Capital analyst Ben Hendrix maintains Chemed (NYSE:CHE) with a Outperform and lowers the price target from $712 to $697.
RBC Capital Maintains Outperform on Chemed, Lowers Price Target to $697
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.